Abstract
Diabetes mellitus (DM) is a chronic disease that results in a variety of systemic complications. Recently, stem cell-based therapies have been proposed as potential modalities to manage DM related complications. Mesenchymal stem cell (MSC) based therapies are often considered as an ideal stem cell-based treatment for DM management due to their immunosuppressive characteristics, anti-inflammatory properties and differentiation potential. While MSCs show tremendous promise, the underlying functional deficits of MSCs in DM patients is not well understood. Using the MEDLINE database to define these functional deficits, our search yielded 1826 articles of which 33 met our inclusion criteria. This allowed us to review the topic and illuminate four major molecular categories by which MSCs are compromised in both Type 1 DM and Type II DM models which include: (1) changes in angiogenesis/vasculogenesis, (2) altered pro-inflammatory cytokine secretion, (3) increased oxidative stress markers and (4) impaired cellular differentiation and decreased proliferation. Knowledge of the deficits in MSC function will allow us to more clearly assess the efficacy of potential biologic therapies for reversing these dysfunctions when treating the complications of diabetic disease.
Similar content being viewed by others
References
Centers for Disease Control and Prevention (2017) National Diabetes Statistics Report (2017): estimate of diabetes and its burden in the United States. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Federation ID (2017) IDF Diabetes Atlas. International Diabetes Federation, Brussels
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414(6865):813–820. https://doi.org/10.1038/414813a
van de Vyver M (2017) Intrinsic mesenchymal stem cell dysfunction in diabetes mellitus: implications for autologous cell therapy. Stem Cells Dev 26(14):1042–1053. https://doi.org/10.1089/scd.2017.0025
Williams AR, Hare JM (2011) Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res 109(8):923–940. https://doi.org/10.1161/circresaha.111.243147
Mizuno H, Tobita M, Uysal AC (2012) Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells 30(5):804–810. https://doi.org/10.1002/stem.1076
Nagaishi K, Mizue Y, Chikenji T, Otani M, Nakano M, Konari N, Fujimiya M (2016) Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep 6:34842. https://doi.org/10.1038/srep34842
de Paula DRM, Capuano V, Filho DM, Carneiro A, de Oliveira Crema V, de Oliveira LF, Rodrigues ARA, Montano N, da Silva VJD (2017) Biological properties of cardiac mesenchymal stem cells in rats with diabetic cardiomyopathy. Life Sci 188:45–52. https://doi.org/10.1016/j.lfs.2017.08.034
Baban B, Liu JY, Payne S, Abebe W, Yu JC, Mozaffari MS (2016) Status of stem cells in diabetic nephropathy: predictive and preventive potentials. EPMA J 7:21. https://doi.org/10.1186/s13167-016-0070-6
Beltramo E, Lopatina T, Berrone E, Mazzeo A, Iavello A, Camussi G, Porta M (2014) Extracellular vesicles derived from mesenchymal stem cells induce features of diabetic retinopathy in vitro. Acta Diabetol 51(6):1055–1064. https://doi.org/10.1007/s00592-014-0672-1
Parajuli A, Liu C, Li W, Gu X, Lai X, Pei S, Price C, You L, Lu XL, Wang L (2015) Bone’s responses to mechanical loading are impaired in type 1 diabetes. Bone 81:152–160. https://doi.org/10.1016/j.bone.2015.07.012
Thomas SWAD, Lakey JRT, Krishnan R, Banyard DA, Salibian AA, Wirth GA, Toranto J, Paydar K, Evans GRD (2014) Adipose derived stem cells and diabetic wound healing: a promising therapeutic modality. CellR4 2(6):e1309
Kuo YR, Wang CT, Cheng JT, Kao GS, Chiang YC, Wang CJ (2016) Adipose-derived stem cells accelerate diabetic wound healing through the induction of autocrine and paracrine effects. Cell Transpl 25(1):71–81. https://doi.org/10.3727/096368915x687921
Gao D, Gu C, Wu Y, Xie J, Yao B, Li J, Feng C, Wang J, Wu X, Huang S, Fu X (2014) Mesenchymal stromal cells enhance wound healing by ameliorating impaired metabolism in diabetic mice. Cytotherapy 16(11):1467–1475. https://doi.org/10.1016/j.jcyt.2014.05.014
Hoffstad O, Mitra N, Walsh J, Margolis DJ (2015) Diabetes, lower-extremity amputation, and death. Diab Care 38(10):1852–1857. https://doi.org/10.2337/dc15-0536
Kim H, Han JW, Lee JY, Choi YJ, Sohn YD, Song M, Yoon YS (2015) Diabetic mesenchymal stem cells are ineffective for improving limb ischemia due to their impaired angiogenic capability. Cell Transpl 24(8):1571–1584. https://doi.org/10.3727/096368914x682792
Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T (2016) Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int 2016:6901286. https://doi.org/10.1155/2016/6901286
Fernandes M, Valente SG, Sabongi RG, Gomes Dos Santos JB, Leite VM, Ulrich H, Nery AA, da Silva Fernandes MJ (2018) Bone marrow-derived mesenchymal stem cells versus adipose-derived mesenchymal stem cells for peripheral nerve regeneration. Neural Regen Res 13(1):100–104. https://doi.org/10.4103/1673-5374.224378
Lin CS, Xin ZC, Dai J, Lue TF (2013) Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges. Histol Histopathol 28(9):1109–1116. https://doi.org/10.14670/hh-28.1109
Li CY, Wu XY, Tong JB, Yang XX, Zhao JL, Zheng QF, Zhao GB, Ma ZJ (2015) Comparative analysis of human mesenchymal stem cells from bone marrow and adipose tissue under xeno-free conditions for cell therapy. Stem Cell Res Ther 6:55. https://doi.org/10.1186/s13287-015-0066-5
Cheng R, Ma JX (2015) Angiogenesis in diabetes and obesity. Rev Endocr Metab Disord 16(1):67–75. https://doi.org/10.1007/s11154-015-9310-7
Risau W, Sariola H, Zerwes HG, Sasse J, Ekblom P, Kemler R, Doetschman T (1988) Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. Development 102(3):471–478
Rezaie J, Mehranjani MS, Rahbarghazi R, Shariatzadeh MA (2018) Angiogenic and restorative abilities of human mesenchymal stem cells were reduced following treatment with serum from diabetes mellitus type 2 patients. J Cell Biochem 119(1):524–535. https://doi.org/10.1002/jcb.26211
Ribot J, Caliaperoumal G, Paquet J, Boisson-Vidal C, Petite H, Anagnostou F (2017) Type 2 diabetes alters mesenchymal stem cell secretome composition and angiogenic properties. J Cell Mol Med 21(2):349–363. https://doi.org/10.1111/jcmm.12969
Kase S, He S, Sonoda S, Kitamura M, Spee C, Wawrousek E, Ryan SJ, Kannan R, Hinton DR (2010) AlphaB-crystallin regulation of angiogenesis by modulation of VEGF. Blood 115(16):3398–3406. https://doi.org/10.1182/blood-2009-01-197095
Shi Y, Su C, Wang JT, Du B, Dong LJ, Liu AH, Li XR (2015) Temporal and spatial changes in VEGF, alphaA- and alphaB-crystallin expression in a mouse model of oxygen-induced retinopathy. Int J Clin Exp Med 8(3):3349–3359
DiPersio JF (2011) Diabetic stem-cell “mobilopathy”. N Engl J Med 365(26):2536–2538. https://doi.org/10.1056/NEJMcibr1112347
Rezabakhsh A, Cheraghi O, Nourazarian A, Hassanpour M, Kazemi M, Ghaderi S, Faraji E, Rahbarghazi R, Avci CB, Bagca BG, Garjani A (2017) Type 2 diabetes inhibited human mesenchymal stem cells angiogenic response by over-activity of the autophagic pathway. J Cell Biochem 118(6):1518–1530. https://doi.org/10.1002/jcb.25814
Vestweber D (2008) VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 28(2):223–232. https://doi.org/10.1161/atvbaha.107.158014
Yuan SM (2015) Alpha-smooth muscle actin and ACTA2 gene expressions in vasculopathies. Braz J Cardiovasc Surg 30(6):644–649. https://doi.org/10.5935/1678-9741.20150081
Arnaoutova I, Kleinman HK (2010) In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc 5(4):628–635. https://doi.org/10.1038/nprot.2010.6
Gong J, Meng HB, Hua J, Song ZS, He ZG, Zhou B, Qian MP (2014) The SDF-1/CXCR4 axis regulates migration of transplanted bone marrow mesenchymal stem cells towards the pancreas in rats with acute pancreatitis. Mol Med Rep 9(5):1575–1582. https://doi.org/10.3892/mmr.2014.2053
De Becker A, Riet IV (2016) Homing and migration of mesenchymal stromal cells: how to improve the efficacy of cell therapy? World J Stem Cells 8(3):73–87. https://doi.org/10.4252/wjsc.v8.i3.73
Jumabay M, Moon JH, Yeerna H, Bostrom KI (2015) Effect of diabetes mellitus on adipocyte-derived stem cells in rat. J Cell Physiol 230(11):2821–2828. https://doi.org/10.1002/jcp.25012
Rennert RC, Sorkin M, Januszyk M, Duscher D, Kosaraju R, Chung MT, Lennon J, Radiya-Dixit A, Raghvendra S, Maan ZN, Hu MS, Rajadas J, Rodrigues M, Gurtner GC (2014) Diabetes impairs the angiogenic potential of adipose-derived stem cells by selectively depleting cellular subpopulations. Stem Cell Res Ther 5(3):79. https://doi.org/10.1186/scrt468
Cianfarani F, Toietta G, Di Rocco G, Cesareo E, Zambruno G, Odorisio T (2013) Diabetes impairs adipose tissue-derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen 21(4):545–553. https://doi.org/10.1111/wrr.12051
Jin P, Zhang X, Wu Y, Li L, Yin Q, Zheng L, Zhang H, Sun C (2010) Streptozotocin-induced diabetic rat-derived bone marrow mesenchymal stem cells have impaired abilities in proliferation, paracrine, antiapoptosis, and myogenic differentiation. Transpl Proceed 42(7):2745–2752. https://doi.org/10.1016/j.transproceed.2010.05.145
Nguyen A, Guo J, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD (2016) Stromal vascular fraction: a regenerative reality? Part 1: current concepts and review of the literature. J Plast Reconstr Aesthet Surg 69(2):170–179. https://doi.org/10.1016/j.bjps.2015.10.015
Guo J, Nguyen A, Banyard DA, Fadavi D, Toranto JD, Wirth GA, Paydar KZ, Evans GR, Widgerow AD (2016) Stromal vascular fraction: a regenerative reality? Part 2: mechanisms of regenerative action. J Plast Reconstr Aesthet Surg 69 (2):180–188. https://doi.org/10.1016/j.bjps.2015.10.014
Duh E, Aiello LP (1999) Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 48(10):1899–1906
Gangadaran P, Rajendran RL, Lee HW, Kalimuthu S, Hong CM, Jeong SY, Lee SW, Lee J, Ahn BC (2017) Extracellular vesicles from mesenchymal stem cells activates VEGF receptors and accelerates recovery of hindlimb ischemia. J Controll Release 264:112–126. https://doi.org/10.1016/j.jconrel.2017.08.022
Tahergorabi Z, Khazaei M (2012) Imbalance of angiogenesis in diabetic complications: the mechanisms. Int J Prev Med 3(12):827–838
Xu L, Kanasaki K, Kitada M, Koya D (2012) Diabetic angiopathy and angiogenic defects. Fibrogenes Tissue Repair 5(1):13. https://doi.org/10.1186/1755-1536-5-13
Wirostko B, Wong TY, Simo R (2008) Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res 27(6):608–621. https://doi.org/10.1016/j.preteyeres.2008.09.002
Merino-Gonzalez C, Zuniga FA, Escudero C, Ormazabal V, Reyes C, Nova-Lamperti E, Salomon C, Aguayo C (2016) Mesenchymal stem cell-derived extracellular vesicles promote angiogenesis: potencial clinical application. Front Physiol 7:24. https://doi.org/10.3389/fphys.2016.00024
Kota SK, Meher LK, Jammula S, Kota SK, Krishna SV, Modi KD (2012) Aberrant angiogenesis: the gateway to diabetic complications. Indian J Endocrinol Metab 16(6):918–930. https://doi.org/10.4103/2230-8210.102992
Endo M, Yanagisawa K, Tsuchida K, Okamoto T, Matsushita T, Higuchi M, Matsuda A, Takeuchi M, Makita Z, Koike T (2001) Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy. Horm Metab Res 33 (5):317–322. https://doi.org/10.1055/s-2001-15122
Selim KM, Sahan D, Muhittin T, Osman C, Mustafa O (2010) Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Ind J Ophthalmol 58(5):375–379. https://doi.org/10.4103/0301-4738.67042
Mironidou-Tzouveleki M, Tsartsalis S, Tomos C (2011) Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr Drug Targets 12(1):107–114
Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R (2013) Pathophysiology of diabetic retinopathy. ISRN Ophthalmol. https://doi.org/10.1155/2013/343560
Mazzeo A, Beltramo E, Iavello A, Carpanetto A, Porta M (2015) Molecular mechanisms of extracellular vesicle-induced vessel destabilization in diabetic retinopathy. Acta Diabetol 52(6):1113–1119. https://doi.org/10.1007/s00592-015-0798-9
Kinnaird T, Stabile E, Burnett MS, Lee CW, Barr S, Fuchs S, Epstein SE (2004) Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 94(5):678–685. https://doi.org/10.1161/01.Res.0000118601.37875.Ac
Lai J, Chen F, Chen J, Ruan G, He M, Chen C, Tang J, Wang DW (2017) Overexpression of decorin promoted angiogenesis in diabetic cardiomyopathy via IGF1R-AKT-VEGF signaling. Sci Rep 7:44473. https://doi.org/10.1038/srep44473
Kim YS, Kwon JS, Hong MH, Kang WS, Jeong HY, Kang HJ, Jeong M, Ahn Y (2013) Restoration of angiogenic capacity of diabetes-insulted mesenchymal stem cells by oxytocin. BMC Cell Biol 14:38. https://doi.org/10.1186/1471-2121-14-38
Danalache BA, Paquin J, Donghao W, Grygorczyk R, Moore JC, Mummery CL, Gutkowska J, Jankowski M (2007) Nitric oxide signaling in oxytocin-mediated cardiomyogenesis. Stem Cells 25(3):679–688. https://doi.org/10.1634/stemcells.2005-0610
Cattaneo MG, Chini B, Vicentini LM (2008) Oxytocin stimulates migration and invasion in human endothelial cells. Br J Pharmacol 153(4):728–736. https://doi.org/10.1038/sj.bjp.0707609
Yuan Y, Shi M, Li L, Liu J, Chen B, Chen Y, An X, Liu S, Luo R, Long D, Zhang W, Newsholme P, Cheng J, Lu Y (2016) Mesenchymal stem cell-conditioned media ameliorate diabetic endothelial dysfunction by improving mitochondrial bioenergetics via the Sirt1/AMPK/PGC-1alpha pathway. Clin Sci 130(23):2181–2198. https://doi.org/10.1042/cs20160235
Khan M, Ali F, Mohsin S, Akhtar S, Mehmood A, Choudhery MS, Khan SN, Riazuddin S (2013) Preconditioning diabetic mesenchymal stem cells with myogenic medium increases their ability to repair diabetic heart. Stem Cell Res Ther 4(3):58. https://doi.org/10.1186/scrt207
Madhira SL, Challa SS, Chalasani M, Nappanveethl G, Bhonde RR, Ajumeera R, Venkatesan V (2012) Promise(s) of mesenchymal stem cells as an in vitro model system to depict pre-diabetic/diabetic milieu in WNIN/GR-Ob mutant rats. PloS ONE 7(10):e48061. https://doi.org/10.1371/journal.pone.0048061
Ranganath SH, Levy O, Inamdar MS, Karp JM (2012) Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10(3):244–258. https://doi.org/10.1016/j.stem.2012.02.005
Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, Kyurkchiev S (2014) Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells 6(5):552–570. https://doi.org/10.4252/wjsc.v6.i5.552
van de Vyver M, Niesler C, Myburgh KH, Ferris WF (2016) Delayed wound healing and dysregulation of IL6/STAT3 signalling in MSCs derived from pre-diabetic obese mice. Mol Cell Endocrinol 426:1–10. https://doi.org/10.1016/j.mce.2016.02.003
Nieto-Vazquez I, Fernandez-Veledo S, de Alvaro C, Lorenzo M (2008) Dual role of interleukin-6 in regulating insulin sensitivity in murine skeletal muscle. Diabetes 57(12):3211–3221. https://doi.org/10.2337/db07-1062
Moller DE (2000) Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 11(6):212–217
Qiao YC, Chen YL, Pan YH, Tian F, Xu Y, Zhang XX, Zhao HL (2017) The change of serum tumor necrosis factor alpha in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. PloS ONE 12(4):e0176157. https://doi.org/10.1371/journal.pone.0176157
Ko KI, Coimbra LS, Tian C, Alblowi J, Kayal RA, Einhorn TA, Gerstenfeld LC, Pignolo RJ, Graves DT (2015) Diabetes reduces mesenchymal stem cells in fracture healing through a TNFalpha-mediated mechanism. Diabetologia 58(3):633–642. https://doi.org/10.1007/s00125-014-3470-y
Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H (2003) Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Investig 112(12):1821–1830. https://doi.org/10.1172/jci19451
Qatanani M, Lazar MA (2007) Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21(12):1443–1455. https://doi.org/10.1101/gad.1550907
Oda N, Imamura S, Fujita T, Uchida Y, Inagaki K, Kakizawa H, Hayakawa N, Suzuki A, Takeda J, Horikawa Y, Itoh M (2008) The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism 57(2):268–273. https://doi.org/10.1016/j.metabol.2007.09.011
Aleidi S, Issa A, Bustanji H, Khalil M, Bustanji Y (2015) Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharm J 23(3):250–256. https://doi.org/10.1016/j.jsps.2014.11.011
Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, Hoogeveen RC, Heiss G (2004) Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes 53(9):2473–2478
Yu L, Tu Q, Han Q, Zhang L, Sui L, Zheng L, Meng S, Tang Y, Xuan D, Zhang J, Murray D, Shen Q, Cheng J, Kim SH, Dong LQ, Valverde P, Cao X, Chen J (2015) Adiponectin regulates bone marrow mesenchymal stem cell niche through a unique signal transduction pathway: an approach for treating bone disease in diabetes. Stem Cells 33(1):240–252. https://doi.org/10.1002/stem.1844
Zhang B, Liu N, Shi H, Wu H, Gao Y, He H, Gu B, Liu H (2016) High glucose microenvironments inhibit the proliferation and migration of bone mesenchymal stem cells by activating GSK3beta. J Bone Miner Metab 34(2):140–150. https://doi.org/10.1007/s00774-015-0662-6
Huang L, Li C (2000) Leptin: a multifunctional hormone. Cell Res 10(2):81–92. https://doi.org/10.1038/sj.cr.7290038
Meek TH, Morton GJ (2012) Leptin, diabetes, and the brain. Indian J Endocrinol Metab 16(Suppl 3):S534–S542. https://doi.org/10.4103/2230-8210.105568
Perry RJ, Zhang XM, Zhang D, Kumashiro N, Camporez JP, Cline GW, Rothman DL, Shulman GI (2014) Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat Med 20(7):759–763. https://doi.org/10.1038/nm.3579
Flier JS (2012) Hormone resistance in diabetes and obesity: insulin, leptin, and FGF21. Yale J Biol Med 85(3):405–414
Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070. https://doi.org/10.1161/circresaha.110.223545
Nigro E, Scudiero O, Monaco ML, Palmieri A, Mazzarella G, Costagliola C, Bianco A, Daniele A (2014) New insight into adiponectin role in obesity and obesity-related diseases. BioMed Res Int 2014:658913. https://doi.org/10.1155/2014/658913
Denu RA, Hematti P (2016) Effects of oxidative stress on mesenchymal stem cell biology. Oxid Med Cell Longev 2016:2989076. https://doi.org/10.1155/2016/2989076
Ha H, Hwang IA, Park JH, Lee HB (2008) Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diab Res Clin Pract 82(Suppl 1):S42–S45. https://doi.org/10.1016/j.diabres.2008.09.017
Lee HB, Yu MR, Yang Y, Jiang Z, Ha H (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14(8 Suppl 3):S241–S245
Hakki Kalkan I, Suher M (2013) The relationship between the level of glutathione, impairment of glucose metabolism and complications of diabetes mellitus. Pak J Med Sci 29(4):938–942
Ali F, Aziz F, Wajid N (2017) Effect of type 2 diabetic serum on the behavior of Wharton’s jelly-derived mesenchymal stem cells in vitro. Chronic Dis Transl Med 3(2):105–111. https://doi.org/10.1016/j.cdtm.2017.02.006
Yan J, Tie G, Wang S, Messina KE, DiDato S, Guo S, Messina LM (2012) Type 2 diabetes restricts multipotency of mesenchymal stem cells and impairs their capacity to augment postischemic neovascularization in db/db mice. J Am Heart Assoc 1(6):e002238. https://doi.org/10.1161/jaha.112.002238
Schroder K, Wandzioch K, Helmcke I, Brandes RP (2009) Nox4 acts as a switch between differentiation and proliferation in preadipocytes. Arterioscler Thromb Vasc Biol 29 (2):239–245. https://doi.org/10.1161/atvbaha.108.174219
Nowotny K, Jung T, Hohn A, Weber D, Grune T (2015) Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules 5(1):194–222. https://doi.org/10.3390/biom5010194
Singh VP, Bali A, Singh N, Jaggi AS (2014) Advanced glycation end products and diabetic complications. Korean J Physiol Pharmacol 18(1):1–14. https://doi.org/10.4196/kjpp.2014.18.1.1
Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A (2003) Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 375(Pt 3):581–592. https://doi.org/10.1042/bj20030763
Xue J, Rai V, Singer D, Chabierski S, Xie J, Reverdatto S, Burz DS, Schmidt AM, Hoffmann R, Shekhtman A (2011) Advanced glycation end product recognition by the receptor for AGEs. Structure 19(5):722–732. https://doi.org/10.1016/j.str.2011.02.013
Aikawa E, Fujita R, Asai M, Kaneda Y, Tamai K (2016) Receptor for advanced glycation end products-mediated signaling impairs the maintenance of bone marrow mesenchymal stromal cells in diabetic model mice. Stem Cells Dev 25(22):1721–1732. https://doi.org/10.1089/scd.2016.0067
Stolzing A, Sellers D, Llewelyn O, Scutt A (2010) Diabetes induced changes in rat mesenchymal stem cells. Cells Tissues Organs 191(6):453–465. https://doi.org/10.1159/000281826
Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T (2007) The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res 39(12):871–875. https://doi.org/10.1055/s-2007-991157
Banyard DA, Salibian AA, Widgerow AD, Evans GR (2015) Implications for human adipose-derived stem cells in plastic surgery. J Cell Mol Med 19(1):21–30. https://doi.org/10.1111/jcmm.12425
Deng X, Xu M, Shen M, Cheng J (2018) Effects of type 2 diabetic serum on proliferation and osteogenic differentiation of mesenchymal stem cells. J Diab Res 2018:5765478. https://doi.org/10.1155/2018/5765478
Moseley KF, Doyle ME, Jan De Beur SM (2018) Diabetic serum from older women increases adipogenic differentiation in mesenchymal stem cells. Endocr Res. https://doi.org/10.1080/07435800.2018.1441868
Barbagallo I, Li Volti G, Galvano F, Tettamanti G, Pluchinotta FR, Bergante S, Vanella L (2017) Diabetic human adipose tissue-derived mesenchymal stem cells fail to differentiate in functional adipocytes. Exp Biol Med 242(10):1079–1085. https://doi.org/10.1177/1535370216681552
Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44(7):1013–1023
Winzell MS, Ahren B (2004) The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. Diabetes 53(Suppl 3):S215–S219
Lee H, Lee YJ, Choi H, Seok JW, Yoon BK, Kim D, Han JY, Lee Y, Kim HJ, Kim JW (2017) SCARA5 plays a critical role in the commitment of mesenchymal stem cells to adipogenesis. Sci Rep 7(1):14833. https://doi.org/10.1038/s41598-017-12512-2
Brown ML, Yukata K, Farnsworth CW, Chen DG, Awad H, Hilton MJ, O’Keefe RJ, Xing L, Mooney RA, Zuscik MJ (2014) Delayed fracture healing and increased callus adiposity in a C57BL/6J murine model of obesity-associated type 2 diabetes mellitus. PloS ONE 9(6):e99656. https://doi.org/10.1371/journal.pone.0099656
Silva JC, Sampaio P, Fernandes MH, Gomes PS (2015) The osteogenic priming of mesenchymal stem cells is impaired in experimental diabetes. J Cell Biochem 116(8):1658–1667. https://doi.org/10.1002/jcb.25126
Kornicka K, Houston J, Marycz K (2018) Dysfunction of mesenchymal stem cells isolated from metabolic syndrome and type 2 diabetic patients as result of oxidative stress and autophagy may limit their potential therapeutic use. Stem Cell Rev 14(3):337–345. https://doi.org/10.1007/s12015-018-9809-x
Sundararaghavan V, Mazur MM, Evans B, Liu J, Ebraheim NA (2017) Diabetes and bone health: latest evidence and clinical implications. Ther Adv Musculoskelet Dis 9(3):67–74. https://doi.org/10.1177/1759720x16687480
Wang W, Zhang X, Zheng J, Yang J (2010) High glucose stimulates adipogenic and inhibits osteogenic differentiation in MG-63 cells through cAMP/protein kinase A/extracellular signal-regulated kinase pathway. Mol Cell Biochem 338(1–2):115–122. https://doi.org/10.1007/s11010-009-0344-6
Wang J, Wang B, Li Y, Wang D, Lingling E, Bai Y, Liu H (2013) High glucose inhibits osteogenic differentiation through the BMP signaling pathway in bone mesenchymal stem cells in mice. EXCLI J 12:584–597
Cramer C, Freisinger E, Jones RK, Slakey DP, Dupin CL, Newsome ER, Alt EU, Izadpanah R (2010) Persistent high glucose concentrations alter the regenerative potential of mesenchymal stem cells. Stem Cells Dev 19(12):1875–1884. https://doi.org/10.1089/scd.2010.0009
Gu Z, Jiang J, Xia Y, Yue X, Yan M, Tao T, Cao X, Da Z, Liu H, Liu H, Miao Y, Li L, Wang Z (2013) p21 is associated with the proliferation and apoptosis of bone marrow-derived mesenchymal stem cells from non-obese diabetic mice. Exp Clin Endocrinol Diab 121(10):607–613. https://doi.org/10.1055/s-0033-1354380
Meng Y, Ji J, Tan W, Guo G, Xia Y, Cheng C, Gu Z, Wang Z (2016) Involvement of autophagy in the procedure of endoplasmic reticulum stress introduced apoptosis in bone marrow mesenchymal stem cells from nonobese diabetic mice. Cell Biochem Funct 34(1):25–33. https://doi.org/10.1002/cbf.3161
Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL (2002) Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 105(3):373–379
Gupta N, Mansoor S, Sharma A, Sapkal A, Sheth J, Falatoonzadeh P, Kuppermann B, Kenney M (2013) Diabetic retinopathy and VEGF. Open Ophthalmol J 7:4–10. https://doi.org/10.2174/1874364101307010004
Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diab Care 32(9):1663–1668. https://doi.org/10.2337/dc09-0533
Sekhar RV, McKay SV, Patel SG, Guthikonda AP, Reddy VT, Balasubramanyam A, Jahoor F (2011) Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diab Care 34(1):162–167. https://doi.org/10.2337/dc10-1006
Rennert RC, Januszyk M, Sorkin M, Rodrigues M, Maan ZN, Duscher D, Whittam AJ, Kosaraju R, Chung MT, Paik K, Li AY, Findlay M, Glotzbach JP, Butte AJ, Gurtner GC (2016) Microfluidic single-cell transcriptional analysis rationally identifies novel surface marker profiles to enhance cell-based therapies. Nat Commun 7:11945. https://doi.org/10.1038/ncomms11945
Banyard DA, Sarantopoulos CN, Borovikova AA, Qiu X, Wirth GA, Paydar KZ, Haun JB, Evans GR, Widgerow AD (2016) Phenotypic analysis of stromal vascular fraction after mechanical shear reveals stress-induced progenitor populations. Plast Reconstr Surg 138(2):237e–247e. https://doi.org/10.1097/prs.0000000000002356
Vizoso FJ, Eiro N, Cid S, Schneider J, Perez-Fernandez R (2017) Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. Int J Mol Sci 18 (9). https://doi.org/10.3390/ijms18091852
Mulder GD, Lee DK, Jeppesen NS (2012) Comprehensive review of the clinical application of autologous mesenchymal stem cells in the treatment of chronic wounds and diabetic bone healing. Int Wound J 9(6):595–600. https://doi.org/10.1111/j.1742-481X.2011.00922.x
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https://doi.org/10.1371/journal.pmed1000097
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors whose names are listed immediately above certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Rights and permissions
About this article
Cite this article
Fijany, A., Sayadi, L.R., Khoshab, N. et al. Mesenchymal stem cell dysfunction in diabetes. Mol Biol Rep 46, 1459–1475 (2019). https://doi.org/10.1007/s11033-018-4516-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-018-4516-x